Literature DB >> 19758202

HLA in Portuguese systemic lupus erythematosus patients and their relation to clinical features.

Carlos Vasconcelos1, Claudia Carvalho, Bárbara Leal, Clara Pereira, Andreia Bettencourt, Paulo P Costa, António Marinho, Paulo Barbosa, Isabel Almeida, Fátima Farinha, Teresa Mendonça, João Araujo Correia, Denisa Mendonça, Berta Martins.   

Abstract

Systemic lupus erythematosus (SLE) is a clinically heterogeneous disease translating the different genetic and environmental factors involved. Polymorphisms at several loci, including the major histocompatibility complex (MHC), have been associated worldwide with SLE, although inconsistencies exist among these studies mainly due to genetic heterogeneity between populations and sample characteristics. The aim of the present study was to investigate in Portuguese SLE the association of HLA-DRB1 alleles with clinical patterns of the disease and severity. Two hundred eighteen Portuguese patients with SLE--42% of whom had kidney involvement--were studied for HLA-DRB1. Clinical and laboratory manifestations were correlated with HLA allele frequencies. HLA-DRB1 * 03 allele frequency was significantly higher in SLE patients--as a whole and as either with or without renal involvement--compared to controls, while HLA-DRB1 * 09 and DRB1 * 13 allele frequencies were decreased. Regarding the relationship with the presence or absence of specific clinical manifestations, it was only found that HLA-DRB1 * 08 allele frequency was increased in patients with neurological involvement. No association with the presence or absence of anti-dsDNA, anti-sm or antiphospholipid antibodies, or antiphospholipid syndrome, was observed. These results were reproducible when analysis was repeated only with patients with more than 5 years of evolution. As in other populations HLA-DRB1 * 03 is a susceptibility allele in Portuguese SLE patients, while HLA-DRB1 * 09 and DRB1 * 13 alleles may be protective alleles, not only for the disease, but for the development of nephritis. No correlations with the different clinical manifestations were found, except with the neurological system.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19758202     DOI: 10.1111/j.1749-6632.2009.04873.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  10 in total

Review 1.  Exploring the etiopathogenesis of systemic lupus erythematosus: a genetic perspective.

Authors:  Ali Javinani; Amir Ashraf-Ganjouei; Saeed Aslani; Ahmadreza Jamshidi; Mahdi Mahmoudi
Journal:  Immunogenetics       Date:  2019-01-22       Impact factor: 2.846

Review 2.  The beneficial role of vitamin D in systemic lupus erythematosus (SLE).

Authors:  Khanh vinh quốc Luong; Lan Thi Hoàng Nguyễn
Journal:  Clin Rheumatol       Date:  2012-07-17       Impact factor: 2.980

Review 3.  The role of common protective alleles HLA-DRB1*13 among systemic autoimmune diseases.

Authors:  H Furukawa; S Oka; N Tsuchiya; K Shimada; A Hashimoto; S Tohma; A Kawasaki
Journal:  Genes Immun       Date:  2016-11-10       Impact factor: 2.676

4.  TNF promoter -308 G>A and LTA 252 A>G polymorphisms in Portuguese patients with systemic lupus erythematosus.

Authors:  Maria José Santos; Diana Carmona-Fernandes; Joana Caetano-Lopes; Inês P Perpétuo; Bruno Vidal; Susana Capela; José Canas da Silva; João Eurico Fonseca
Journal:  Rheumatol Int       Date:  2011-05-05       Impact factor: 2.631

5.  Relation between HLA typing and clinical presentations in Systemic Lupus Erythematosus patients in Al-Qassim region, Saudi Arabia.

Authors:  Walid Wadi; Noor Eldeen A M Elhefny; Essam H Mahgoub; Adel Almogren; Khaled D Hamam; Hamad A Al-Hamed; Gasim I Gasim
Journal:  Int J Health Sci (Qassim)       Date:  2014-04

6.  Association of HLA-DRB1*15 and HLADQB1*06 with SLE in Saudis.

Authors:  Saleh Al-Motwee; Dunia Jawdat; Ghassan S Jehani; Hanan Anazi; Abdullah Shubaili; Paul Sutton; Aytul F Uyar; Ali H Hajeer
Journal:  Ann Saudi Med       Date:  2013 May-Jun       Impact factor: 1.526

7.  Deletions in VANGL1 are a risk factor for antibody-mediated kidney disease.

Authors:  Simon H Jiang; Sevcan Mercan; Ilenia Papa; Max Moldovan; Giles D Walters; Mark Koina; Mitali Fadia; Maurice Stanley; Tom Lea-Henry; Amelia Cook; Julia Ellyard; Brendan McMorran; Madhivanan Sundaram; Russell Thomson; Pablo F Canete; Wendy Hoy; Holly Hutton; Monika Srivastava; Kathryn McKeon; Iñigo de la Rúa Figueroa; Ricard Cervera; Raquel Faria; Sandra D'Alfonso; Mariele Gatto; Vicki Athanasopoulos; Matthew Field; John Mathews; Eun Cho; Thomas D Andrews; A Richard Kitching; Matthew C Cook; Marta Alarcon Riquelme; Melanie Bahlo; Carola G Vinuesa
Journal:  Cell Rep Med       Date:  2021-12-21

8.  Association of HLA-DR1, HLA-DR13, and HLA-DR16 Polymorphisms with Systemic Lupus Erythematosus: A Meta-Analysis.

Authors:  Tingrui Wang; Hong Wang; Lijuan Qiu; Lingling Wu; Huayun Ling; Yu Xue; Ying Zhou; Huijuan Chen; Dong-Qing Ye; Bin Wang
Journal:  J Immunol Res       Date:  2022-04-16       Impact factor: 4.493

9.  The Protective Role of HLA-DRB1(∗)13 in Autoimmune Diseases.

Authors:  Andreia Bettencourt; Cláudia Carvalho; Bárbara Leal; Sandra Brás; Dina Lopes; Ana Martins da Silva; Ernestina Santos; Tiago Torres; Isabel Almeida; Fátima Farinha; Paulo Barbosa; António Marinho; Manuela Selores; João Correia; Carlos Vasconcelos; Paulo P Costa; Berta Martins da Silva
Journal:  J Immunol Res       Date:  2015-10-29       Impact factor: 4.818

Review 10.  Genetic Factors in Systemic Lupus Erythematosus: Contribution to Disease Phenotype.

Authors:  Fulvia Ceccarelli; Carlo Perricone; Paola Borgiani; Cinzia Ciccacci; Sara Rufini; Enrica Cipriano; Cristiano Alessandri; Francesca Romana Spinelli; Antonio Sili Scavalli; Giuseppe Novelli; Guido Valesini; Fabrizio Conti
Journal:  J Immunol Res       Date:  2015-12-21       Impact factor: 4.818

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.